Chiba S, Kashiwagi M, Kobayashi N, Saito M, Matsumoto H
Department of Neurology, Sapporo Medical College.
Rinsho Shinkeigaku. 1993 Jan;33(1):86-8.
Adenosine deaminase (ADA) is a deaminating enzyme consisting of isozymes ADA 1 and ADA 2. We measured the activities of total ADA, ADA 1 and ADA 2 in serum obtained from 42 patients with Parkinson's disease (PD). Patients were divided into 10 cases of stage I, 20 of II, 11 of III and 1 of IV according to the clinical stages described by Hoehn and Yahr. The total and ADA 2 activities were significantly higher in patients as compared with normal controls (p < 0.01, respectively). However, this study did not detect any tendency for elevated total ADA or its isozyme activities with advance in clinical stages described by Hoehn and Yahr. ADA and ADA 2 are thought to have important roles in the regulation of the immune function. On the other hand, recent reports have suggested that immunological abnormality may be responsible for the developing of PD. Our results also suggest that high serum ADA activity may be involved in the pathogenesis of PD through the alteration of the immune function.
腺苷脱氨酶(ADA)是一种由同工酶ADA 1和ADA 2组成的脱氨基酶。我们测定了42例帕金森病(PD)患者血清中总ADA、ADA 1和ADA 2的活性。根据Hoehn和Yahr描述的临床分期,将患者分为I期10例、II期20例、III期11例和IV期1例。与正常对照组相比,患者的总ADA和ADA 2活性显著更高(分别为p < 0.01)。然而,本研究未发现随着Hoehn和Yahr描述的临床分期进展,总ADA或其同工酶活性有升高的趋势。ADA和ADA 2被认为在免疫功能调节中起重要作用。另一方面,最近的报告表明免疫异常可能与PD的发生有关。我们的结果还表明,高血清ADA活性可能通过免疫功能的改变参与PD的发病机制。